Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a transaction on January 5, 2012, where Mrs. K Thomson (Connected Person to Director Mr. P C Thomson) acquired 19,818 ordinary shares. The purchase price was 1,445.87 pence per share. This acquisition resulted from the re-investment of the dividend paid to shareholders on that date.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(c) regarding the notification of the connected person's transaction.
Investor Verification Points
- Verify the total shareholding of Mrs. K Thomson following the acquisition of 19,818 shares.
- Confirm the dividend reinvestment plan terms applicable to the January 5, 2012 payment.
- Review the broader context of the January 2012 dividend payout in the company's full financial statements.